Disability

Discovery World on Market Partners for Blue Star Museum Program

PARKERSBURG, WV / ACCESSWIRE / May 3, 2024 / Discovery World on Market is teaming up with Fight4Vets and Jan…

7 months ago

Veru to Present at the GLP-1 Based Therapeutics Summit

MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

7 months ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low…

7 months ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline…

7 months ago

Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events

Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage…

7 months ago

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines,…

7 months ago

Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression

SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on…

7 months ago

Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

7 months ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months…

7 months ago

Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business developmentMARLBOROUGH, Mass.…

7 months ago